Lapatinib Ditosylate Patent Expiration
Lapatinib Ditosylate is Used for treating advanced or metastatic breast cancer with HER2 overexpression that has not responded to prior treatments. It was first introduced by Novartis Pharmaceuticals Corp
Lapatinib Ditosylate Patents
Given below is the list of patents protecting Lapatinib Ditosylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tykerb | US8821927 | Pharmaceutical composition | Sep 18, 2029 | Novartis |
| Tykerb | US7157466 | Quinazoline ditosylate salt compounds |
Nov 19, 2021
(Expired) | Novartis |
| Tykerb | US6713485 | Heterocyclic compounds |
Sep 29, 2020
(Expired) | Novartis |
| Tykerb | US6727256 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan 08, 2019
(Expired) | Novartis |
| Tykerb | US8513262 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan 08, 2019
(Expired) | Novartis |
| Tykerb | US6391874 | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
Jul 11, 2017
(Expired) | Novartis |
| Tykerb | US6828320 | Heterocyclic compounds |
Jul 11, 2017
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Lapatinib Ditosylate's patents.
Latest Legal Activities on Lapatinib Ditosylate's Patents
Given below is the list recent legal activities going on the following patents of Lapatinib Ditosylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Feb, 2022 | US8821927 |
| Expire Patent Critical
| 27 Sep, 2021 | US8513262 |
| Maintenance Fee Reminder Mailed Critical
| 12 Apr, 2021 | US8513262 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Jun, 2018 | US7157466 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Feb, 2018 | US8821927 |
| Post Issue Communication - Certificate of Correction | 28 Jul, 2015 | US8821927 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 05 Jun, 2015 | US8821927 |
| Email Notification Critical
| 05 Jun, 2015 | US8821927 |
| Email Notification Critical
| 05 Jun, 2015 | US8513262 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 04 Jun, 2015 | US8513262 |
Lapatinib Ditosylate's Family Patents
